Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Free Cash Flow (2017 - 2025)

Historic Free Cash Flow for Arcus Biosciences (RCUS) over the last 9 years, with Q3 2025 value amounting to -$97.0 million.

  • Arcus Biosciences' Free Cash Flow fell 48800.0% to -$97.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$464.0 million, marking a year-over-year decrease of 17455.62%. This contributed to the annual value of -$176.0 million for FY2024, which is 4666.67% up from last year.
  • Latest data reveals that Arcus Biosciences reported Free Cash Flow of -$97.0 million as of Q3 2025, which was down 48800.0% from -$133.0 million recorded in Q2 2025.
  • In the past 5 years, Arcus Biosciences' Free Cash Flow registered a high of $651.0 million during Q1 2022, and its lowest value of -$133.0 million during Q1 2025.
  • Over the past 5 years, Arcus Biosciences' median Free Cash Flow value was -$73.0 million (recorded in 2023), while the average stood at -$37.8 million.
  • Its Free Cash Flow has fluctuated over the past 5 years, first surged by 103057.16% in 2022, then tumbled by 211666.67% in 2025.
  • Over the past 5 years, Arcus Biosciences' Free Cash Flow (Quarter) stood at -$70.4 million in 2021, then grew by 0.51% to -$70.0 million in 2022, then plummeted by 34.29% to -$94.0 million in 2023, then decreased by 7.45% to -$101.0 million in 2024, then increased by 3.96% to -$97.0 million in 2025.
  • Its Free Cash Flow stands at -$97.0 million for Q3 2025, versus -$133.0 million for Q2 2025 and -$133.0 million for Q1 2025.